Istvan Redei,MD


Director, Hematologic Malignancies and Stem Cell Transplant Program, CTCA Chicago

Istvan Redei - Chief, Division of Stem Cell Transplantation, Department of Medical Oncology at Cancer Treatment Centers of America®

I strive to aggressively fight hematologic cancer and provide my patients with treatment options and hope.

CTCA Chicago
2520 Elisha Avenue
Zion, Illinois 60099
Hematologic Oncology
Stem Cell Transplant
Medical school:
Semmelweis Ignác Medical University, Budapest, Hungary
Internal Medicine - New York Medical College/Metropolitan Hospital Center
Hematology/Oncology – Temple University School of Medicine/Fox Chase Cancer Center, Philadelphia, PA
Visiting Fellow – Fred Hutchinson Cancer Research Center, Seattle, WA
Leukemia and Bone Marrow Transplantation – Emory University School of Medicine, Atlanta, GA
Hematology - American Board of Internal Medicine

Dr. Istvan Redei is proud to be part of a growing movement toward patient-oriented cancer care. As the leader of the Hematologic Malignancies and Stem Cell Transplant Program, the experienced hematologist-oncologist cares for patients who are fighting hematologic malignancies such as lymphoma and leukemia at Cancer Treatment Centers of America® (CTCA), Chicago.

Prior to joining CTCA®, Dr. Redei served as Director of the Matched Unrelated Donor Transplant Program at the Emory University School of Medicine in Atlanta. He also served as assistant professor of hematology/oncology at the Winship Cancer Center.

Board certified in hematology, Dr. Redei received his medical degree from Semmelweis University in Budapest, Hungary. He then went on to complete his residency at New York Medical College. He completed a fellowship in hematology at Temple University and a fellowship in oncology at Fox Chase Cancer Center, both in Philadelphia.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.